ArticleThe Journal of infectious diseases2005
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.
Article in The Journal of infectious diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 124 citations in OpenAlex.
- Machine learning aided multiscale modelling of the HIV-1 infection in the presence of NRTI therapy.PeerJ · 2023Article
- Bayesian variable selection using Knockoffs with applications to genomics.Computational statistics · 2022Article
- The evolution of the HIV-1 protease folding stability.Virus evolution · 2022Article
- HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil.Journal of neurovirology · 2021Observational
- The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.BMC infectious diseases · 2020Article
- Genetic variation and function of the HIV-1 Tat protein.Medical microbiology and immunology · 2019Review
- Observational
- Article
- Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.BMC infectious diseases · 2014Article
- Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes.PloS one · 2014Article
- Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease.Biochemistry · 2013Article
- Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.BMC genomics · 2013Article
- Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand.Chemical biology & drug design · 2012Article
- Prediction of mutational tolerance in HIV-1 protease and reverse transcriptase using flexible backbone protein design.PLoS computational biology · 2012Article
- A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.BMC bioinformatics · 2011Article
- Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.PloS one · 2011Article
- Structures of reverse transcriptase pre- and post-excision complexes shed new light on HIV-1 AZT resistance.Viruses · 2011Article
- HIV-1 protease mutations and protease inhibitor cross-resistance.Antimicrobial agents and chemotherapy · 2010Article
- Co-lethality studied as an asset against viral drug escape: the HIV protease case.Biology direct · 2010Article
- Mining protein dynamics from sets of crystal structures using "consensus structures".Protein science : a publication of the Protein Society · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Background. It is important, for drug-resistance surveillance, to identify human immunodeficiency virus type 1 (HIV-1) strains that have undergone antiretroviral drug selection.Methods. We compared the prevalence of protease and reverse-transcriptase (RT) mutations in HIV-1 sequences from persons with and without previous treatment with protease inhibitors (PIs), nucleoside RT inhibitors (NRTIs), and nonnucleoside RT inhibitors (NNRTIs). Treatment-associated mutations in protease isolates from 5867 persons and RT isolates from 6247 persons were categorized by whether they were polymorphic (prevalence, >0.5%) in untreated individuals and whether they were established drug-resistance mutations. New methods were introduced to minimize misclassification from transmitted resistance, population stratification, sequencing artifacts, and multiple hypothesis testing.Results. Some 36 established and 24 additional nonpolymorphic protease mutations at 34 positions were related to PI treatment, 21 established and 22 additional nonpolymorphic RT mutations at 24 positions with NRTI treatment, and 15 established and 11 additional nonpolymorphic RT mutations at 15 positions with NNRTI treatment. In addition, 11 PI-associated and 1 NRTI-associated established mutations were polymorphic in viruses from untreated persons.Conclusions. Established drug-resistance mutations encompass only a subset of treatment-associated mutations; some of these are polymorphic in untreated persons. In contrast, nonpolymorphic treatment-associated mutations may be more sensitive and specific markers of transmitted HIV-1 drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.